Physician profile
David E Aftergood
NPI 1639259328
$29,597.83
in general payments reported to CMS, 2019-2025
75 companies · $4,449 in 2025
The $4,449 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,989 · 2020: $2,785 · 2021: $4,274 · 2022: $4,635 · 2023: $4,584 · 2024: $4,884 · 2025: $4,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Gift: $119 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,687.43 |
| Gift | $118.80 |
| Education | $110.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,087.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,821.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,254.06 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $1,887.28 | 2019-2025 | Ubrelvy, Synthroid |
| Corcept Therapeutics | $1,576.63 | 2019-2025 | Korlym |
| Amgen INC. | $1,398.71 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $1,337.81 | 2019-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $1,210.61 | 2019-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $1,135.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $936.28 | 2019-2023 | Farxiga |
| Ibsa Pharma INC. | $917.64 | 2019-2025 | Tirosint, Licart, Tirosint |
| Radius Health, INC. | $917.29 | 2019-2025 | Tymlos |
| Insulet Corporation | $875.75 | 2019-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $760.15 | 2020-2025 | Isturisa, Signifor Lar |
| Dexcom, INC. | $688.64 | 2019-2025 | Dexcom G6 Transmitter |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $543.27 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $458.57 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $433.58 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Currax Pharmaceuticals LLC | $410.95 | 2019-2024 | Contrave, Nexletol, Nexlizet |
| Merck Sharp & Dohme LLC | $403.93 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $352.24 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $321.65 | 2019-2025 | Strensiq |
| Horizon Therapeutics Plc | $316.73 | 2019-2023 | Tepezza |
| Janssen Pharmaceuticals, INC | $272.87 | 2019 | |
| Antares Pharma, INC. | $271.65 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Vistapharm, INC. | $256.58 | 2021 | |
| Amarin Pharma, INC. | $235.96 | 2019-2022 | |
| Medtronic, INC. | $226.28 | 2021-2024 | Accurian |
| Becton, Dickinson and Company | $222.55 | 2021-2022 | |
| Madrigal Pharmaceuticals | $190.85 | 2025 | Rezdiffra |
| Embecta Corp. | $159.68 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ascensia Diabetes Care US INC. | $155.46 | 2023-2025 | |
| Endo Pharmaceuticals INC. | $141.58 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $138.76 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $134.85 | 2023-2025 | Crysvita |
| Alfasigma USA, INC. | $134.35 | 2021-2022 | |
| Beta Bionics, INC. | $112.01 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $110.93 | 2022-2024 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.97 | 2022-2024 | Xifaxan |
| Lifescan, INC. | $105.77 | 2019-2022 | |
| Alvogen INC | $93.71 | 2023-2025 | Teriparatide |
| Zealand Pharma US, INC. | $91.39 | 2020-2022 | |
| Eusa Pharma (US) LLC | $84.26 | 2022 | |
| Medtronic Minimed, INC. | $81.49 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $78.43 | 2022-2024 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $74.36 | 2023-2024 | Inpefa |
| Ipsen Biopharmaceuticals, INC | $73.46 | 2019-2021 | |
| Eisai INC. | $64.84 | 2019-2021 | |
| Grt US Holding, INC. | $60.56 | 2021-2022 | |
| Vivus LLC | $60.44 | 2019-2023 | Qsymia |
| Esperion Therapeutics, INC. | $57.53 | 2021-2025 | Nexletol |
| Allergan, INC. | $57.00 | 2020 | |
| Tolmar, INC. | $49.18 | 2023-2024 | |
| Halozyme INC | $48.11 | 2023 | |
| Shire North American Group INC | $47.94 | 2019 | |
| Acella Pharmaceuticals, LLC | $44.68 | 2024-2025 | NP Thyroid 60 |
| Acerus Pharmaceuticals Corporation | $42.16 | 2020-2021 | |
| Astellas Pharma US INC | $42.00 | 2024 | Veozah |
| Intra-Sana Laboratories | $39.01 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Kowa Pharmaceuticals America, INC. | $36.26 | 2021 | |
| Amneal Pharmaceuticals LLC | $35.57 | 2019 | |
| Neurocrine Biosciences, INC. | $35.35 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.17 | 2022 | |
| Senseonics, Incorporated | $27.00 | 2019 | |
| Bigfoot Biomedical INC | $26.35 | 2022 | |
| Sequel Med Tech, LLC | $24.98 | 2025 | Twiist |
| Exact Sciences Corporation | $23.83 | 2023 | Cologuard Collection Kit |
| Amryt Pharma Holdings Ltd | $22.68 | 2023 | Mycapssa |
| Genzyme Corporation | $19.86 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $19.00 | 2019 | |
| Clarus Therapeutics INC. | $18.58 | 2021 | |
| Pfizer INC. | $18.37 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.93 | 2020 | |
| Optos, INC. | $14.67 | 2021 | |
| Medicure Pharma INC. | $13.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Aftergood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.